Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biologics for serologically active clinically quiescent SLE (SACQ SLE)
jRCT1031250057Recruiting
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised trial of belimumab and anifrolumab in systemic lupus erythematosus (SLE) (2 arms). Primary endpoint: Glucocorticoid discontinuation without relapse at Week 96. Started Apr 2025; status: recruiting.
02
Drugs
belimumabanifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT1031250057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250057.